AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03172897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine is administered as a continuous intravenous infusion at a rate of 0.025 mL/kg per h (0.1 μg/kg per h) from study recruitment in the ICU for no more than 72 hours.
Study NCT03172897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (normal saline)
Description: Placebo (normal saline) is administered as a continuous intravenous infusion at a rate of 0.025 mL/kg per h from study recruitment in the ICU for no more than 72 hours.
Study NCT00910858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Description: Recombinant human erythropoietin (rhu-EPO) subcutaneous injection of 40,000 units.
Study NCT02872402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Women who are still breastfeeding at the first postpartum visit will be encouraged to pursue. References to local breastfeeding supporting groups will be done, if needed. The intervention will be conducted in order to reach recommendations for food servings and nutrient needs. Particular attention will be paid to increase fruits, vegetables, fish and whole grains intake, and decrease added sugars and high fat meat/dairy products. Women will be strongly encouraged to be active at least 150 min/week. They will be provided with targeted strategies for exercising, types of exercises and tips for including physical activity into the daily routine as well as fun exercises for the whole family.
Study NCT02872402 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control lifestyle intervention
Description: Participants in the control group will receive standard lifestyle recommendations in the form of written information at each visit.
Study NCT02844374 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Functional stereotaxic exploration
Description: Visual analysis : in order to define the level of cortical resections. Epileptogenic maps : calculated for each crisis and for all crisis in general. Connectivity maps : calculated for each site stimulated at low-frequency. Post-operative evaluation : in order to assess the extent of resection.
Study NCT00711503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anakinra
Description: The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (IL-1Ra, anakinra, Kineret®, Amgen, CA, USA) \[13\] at a dose of 100 mg once daily by subcutaneous injection
Study NCT00711503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: The patients are instructed to administer placebo (saline) once daily by subcutaneous injection
Study NCT02025582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio Tape of the Ankle
Description: Tibialis anterior facilitation/ gastrocnemius inhibition: Taping to be worn 3-5 days and repeated x 1
Study NCT01214330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient-Collected Cervical Pap Smear
Description: Patient-Collected Cervical Papanicolaou Smear
Study NCT02832908 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Change from semi-seated position to supine
Description: from semi-seated position (30°) to lying position
Study NCT01767441 — intervention group
Intervention type: PROCEDURE
Intervention: Roux-en-Y-gastric bypass
Description: Gastric bypass consisted of creation of a 15-20 ml gastric pouch, a 150 cm Roux limb, and a 50 cm biliopancreatic limb
Study NCT01767441 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic adjustable gastric banding
Description: Gastric banding functions by limiting food intake after the placement of an inflatable tube around the stomach just below the gastroesophageal junction, which allows for adjustment of the size of the outlet via the addition or removal of saline through a subcutaneous port.
Study NCT00616148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YKP3089
Description: Oral dosage form
Study NCT00616148 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00277238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPG10101
Description: CPG10101, subcutaneous, 0.2mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks
Study NCT00277238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPG10101
Description: CPG10101, subcutaneous, 0.5mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks
Study NCT00277238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 12wks
Study NCT03253653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Waterpipe smoking
Description: In a repeated measures design, 50 adult male and female exclusive WP tobacco smokers will smoke WP tobacco weekly over a 3-week study period with 3 WP smoking practices as follows: 1) using room temperature water in the WP jar, 2) adding ice cubes to the water in the WP jar, and 3) using a charcoal-free electronic WP head to heat the tobacco. Six Spot first morning urine samples will be provided by participants. Two urine samples per each of the 3 smoking sessions. Urine samples will be provided on the day of the WP tobacco smoking session and the following day. Physiological measures will be taken at Baseline during the office visit and before and after each of the 3 WP tobacco smoking sessions.
Study NCT02866292 — intervention group
Intervention type: OTHER
Intervention: Pelvic floor muscle and sexual function evaluation
Description: PFM evaluation was performed by vaginal palpation and vaginal squeeze pressure. During vaginal palpation the physiotherapist introduced the index and middle fingers about 4cm inside the vagina, and requested to hold the maximum contraction of the PFM. Muscle function was classified by the Oxford Scale Modified.~The vaginal squeeze pressure was measured through Perineometer.To obtain the measurements, the subjects remained positioning and vaginal sensor was introduced into the vaginal cavity. The women were oriented and motivated verbally to perform three voluntary maximal contractions sustained for five seconds and one minute interval between them.~Sexual function was evaluated by the Female Sexual Function Index (FSFI) questionnaire. The questionnaire consists of 19 multiple-choice questions, which involves six sexual response domains: desire, arousal, lubrication, orgasm, satisfaction and pain.
Study NCT01994434 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Decompression of the ulnar nerve
Description: Surgical decompression of the Guyon's canal and ganglion excision
Study NCT00771719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftobiprole
Description: Ceftobiprole, 1 G q8h as 4 hour infusions for 2 days
Study NCT03457532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gumarontinib Tablets
Description: 25mg; 50mg; 100mg; 200mg; 400mg; 600mg BID or QD(Decided by SMC accroding to the safty and PK data)
Study NCT01767441 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic sleeve gastrectomy
Description: Sleeve gastrectomy involved a gastric reduction of 75 to 80% by resecting the stomach alongside a 30-French endoscope beginning 3 cm from pylorus and ending at the angle of His
Study NCT01767441 — intervention group
Intervention type: OTHER
Intervention: diet treatment
Description: Hypocaloric diet providing a 1000 Kcal/d deficit from total energy expenditure assessed by indirect calorimetry and physical activity determination
Study NCT00263705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant capecitabine
Description: Capecitabine 2000 mg/m² daily six cycles
Study NCT00263705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine in aduvant setting
Description: capecitabine in aduvant setting in ederly with breast cancer
Study NCT01775059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integrated sensor and infusion set.
Study NCT01605552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beating the Blues (BtB)
Description: BtB is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions. General topics covered include identifying and challenging automatic thoughts, cognitive errors, core beliefs, and attributional styles; activity scheduling; problem solving; graded exposure; task breakdown; sleep management; and relapse prevention. In addition to session work, patients are assigned homeworks that are customized to their needs and reviewed at the start of each session. A progress report, including whether the patient is experiencing suicidal ideation, is generated at the end of each session.
Study NCT01605552 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Patients randomized to usual care will be informed that they have clinically significant depressive symptoms and will be encouraged to follow-up with their primary care physicians, who will receive a letter from our team indicating that their patient has elevated depressive symptoms and was randomized to the control condition. The letter will also encourage physicians to follow-up with their patients and will provide a list of local mental health services. Like those in the intervention group, usual care patients will continue to have access to and will receive any medical and mental health services that are part of usual care in the targeted health care systems. Thus, there are no restrictions regarding the care that these patients can receive.
Study NCT01073605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genotonorm
Description: 0.7 IU/kg/week or 0.03 mg/kg/day, daily subcutaneous injection
Study NCT01838499 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI8968
Description: SC injection at baseline, Week 4 and Week 8
Study NCT01838499 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: SC injection at baseline, Week 4 and Week 8
Study NCT03336684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education
Description: Rheumatoid arthritis patients will be provided with disease education literature
Study NCT02246387 — intervention group
Intervention type: PROCEDURE
Intervention: Manchester Operation
Description: A 3- compartment native tissue repair procedure for Pelvic Organ Prolapse.
Study NCT04286893 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Flow mediated vasodilatation
Description: Measurement of brachial artery diameter change before and after limb ischaemia.
Study NCT04286893 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: High resolution ECG
Description: Measurement HRV using high resolution ECG
Study NCT04286893 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood withdrawal
Description: Measurement of endothelial inflammation markers
Study NCT00116584 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: heliox
Description: continuous heliox therapy
Study NCT00116584 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: oxygen
Description: continuous oxygen therapy
Study NCT03254992 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASD - Abstract task
Description: Experimental group using Kinect with more virtual activity.
Study NCT03435614 — intervention group
Intervention type: DRUG
Intervention: Opioids
Description: Once an opioid dose reduction of 10% or greater is achieved, a daily assessment will be conducted by a physician using the DSM-5 criteria for opioid withdrawal. In addition, signs and symptoms of withdrawal will be collected daily by a blinded investigator.
Study NCT03768505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zandelisib (ME-401)
Description: Zandelisib (ME-401) 60 mg
Study NCT03254992 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASD - Tangible task
Description: Experimental group using Keyboard with more real activity.
Study NCT03254992 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TD - Abstract task
Description: Control group using Kinect with more virtual activity.
Study NCT03254992 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TD - Tangible task
Description: Control group using Keyboard with more real activity.
Study NCT00126555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Oral Gefitinib induction therapy given daily for 2 months at 250 mg/day, once a day for 30 days (1 cycle = 30 days) with at least 2 cycles of treatment (60 days) given. After 2 months evaluate for clinical response (15 days) and resectability (60 days). If after 15 days with no tumor response, daily dose doubled (500 mg), and discontinuation if tumor progression.
Study NCT00126555 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Undergo radiation therapy treatments once a day Monday through Friday for about 7 weeks. Each treatment takes about 15 minutes.
Study NCT01073605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genotonorm
Description: 1.4 IU/kg/week or 0.06 mg/kg/day, daily subcutaneous injection
Study NCT01073605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genotonorm
Description: 1.4 IU/kg/week or 0.06 mg/kg/day, daily subcutaneous injection Intermittent treatment (6 months with treatment and 6 months without)
Study NCT02523183 — intervention group
Intervention type: DRUG
Intervention: Medical Cannabis
Description: Pediatric patients with medically refractory epilepsy and treated with medicinal cannabis.
Study NCT02748642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BITS7201A
Description: BITS72014A will be administered on Day 1 in Part A and on Days 1, 28, and 57 in Part B.
Study NCT02748642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to BITS72014A will be administered on Day 1 in Part A and on Days 1, 28, and 57 in Part B.
Study NCT03633123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D_PLEX
Description: D_PLEX is reconstituted into paste and administered in a single application following closure of the fascia, on the fascia suture line, and on the soft tissues of the abdominal wall along the whole length of the surgical wound (including muscle, fat and dermis).
Study NCT03633123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care (SoC)
Description: Prophylactic, pre-operation: 1st or 2nd generation of Cephalosporine family, plus Metronidazole.~Post-operation: this is each participating center standard practice for this type of procedure
Study NCT03633123 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care (SoC)
Description: Prophylactic, pre-operation: 1st or 2nd generation of Cephalosporine family, plus Metronidazole.~Post-operation: this is each participating center standard practice for this type of procedure
Study NCT04676269 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Amnion only
Description: Patients endometrium will be transplanted with amnion only (without seeded cells)
Study NCT04676269 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amnion - endometrium cells
Description: Patients endometrium will be transplanted with amnion seeded with endometrium cells isolated from the patients themselves
Study NCT01424956 — intervention group
Intervention type: DEVICE
Intervention: Automated Breast Ultrasound (ABUS)
Description: Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography.
Study NCT02245776 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell
Description: Intrathecal autologous bone marrow mononuclear cell transplantation
Study NCT00814658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: Galantamine 8 mg/day for one month, followed by 4 weeks of galantamine 16 mg/day. If necessary and well tolerated, dosage of galantamine will be increased to 24 mg/day.
Study NCT03070236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Select questions will be ask in the survey
Study NCT04672551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR Treatment
Description: Eight individual EMDR sessions lasting for 1 hours will be provided over 8 weeks by licensed EMDR therapists from the German-speaking part of Switzerland. Each EMDR session follows a standardized 8-phase protocol.
Study NCT00814658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimodipine
Description: Nimodipine 30 mg 3 times a day (tid).
Study NCT00814658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo three times a day (tid).
Study NCT01449058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: taken orally
Study NCT01449058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: taken orally
Study NCT04676269 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amnion - amnion epithelial cells
Description: Patients endometrium will be transplanted with amnion seeded with amnion epithelial stem cells isolated from other patients' caesarean sectio amnion membrane (tested HLA-DR negative to prevent rejection)
Study NCT02565342 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block
Study NCT01380314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine + Imiquimod
Description: 150 mg x d during 28 days and cream applied every other day during 3 weeks
Study NCT01380314 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Miltefosine 150 mg x day + Placebo
Description: 150 mg x d during 28 days and cream applied every other day during 3 weeks
Study NCT02555709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTP-43742
Description: VTP-43742 administered as an oral capsule once daily
Study NCT00715429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin d
Description: After a two-week wash-in, subjects will take a vitamin D capsule (50,000 units) once daily for 10 days, followed by a once weekly vitamin D (50,000 units) maintenance dose for 7 weeks.
Study NCT00715429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: After a two-week wash-in, subjects will take a placebo capsule once daily for 10 days, followed by a once weekly maintenance dose for 7 weeks.
Study NCT02090101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAKINRA
Study NCT02605980 — intervention group
Intervention type: BEHAVIORAL
Intervention: Sedentary time
Study NCT00492284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: verteporfin
Description: Reduced-fluence Visudyne (25 J/cm2, 300 mW/cm2, 83 seconds)
Study NCT00492284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: verteporfin
Description: Very-low fluence Visudyne (15 J/cm2, 180 mW/cm2, 83 seconds)
Study NCT00492284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: 0.5 mg intravitreal injection
Study NCT00492284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 0.5 mg intravitreal injection
Study NCT03624504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micra Transcatheter Pacing System (TPS)
Description: Treatment of subjects eligible for the single chamber ventricular pacemaker per study requirements
Study NCT03936686 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey tool to assess CVD risk factor knowledge
Description: The survey tool was used to assess the participant's knowledge level and their previous methods of education regarding cardiovascular disease risk factors.
Study NCT04676269 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amnion-EnSC-AESC
Description: Patients endometrium will be transplanted with amnion seeded with endometrium cells-amnion epithelial stem cells co-culture
Study NCT01069042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: All subjects will initially receive 10mg of enalapril and be gradually titrated up to 20mg with blood pressure tolerance for 6 months.
Study NCT01069042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: All subjects will initially receive 10mg of enalapril and be gradually titrated up to 20mg with blood pressure tolerance for 6 months.
Study NCT03034447 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Children and parents are going to inform data regarding socioeconomical status, asthma and rhinitis diagnosis, asthma and rhinitis control, medications, sleep complaints, and sleep habits
Study NCT03034447 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lung Function Test
Description: Children are going to blow in a machine that measures how the lung is working
Study NCT03034447 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Home Sleep Study
Description: Children are going to sleep at home with a device that tells if they stop breathing during sleep
Study NCT02679417 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: 12 weeks of aerobic or resistant exercise